NCT03445013View on ClinicalTrials.gov

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

January 31, 2018

Study Completion Date

February 6, 2018

Conditions

Psoriasis

Interventions

DRUG

SB414 6%

Twice daily

DRUG

Vehicle

Vehicle Comparator

Trial Locations (4)

23502

Novella Site# 114, Norfolk

77845

Novella Site# 249, College Station

78759

Novella Site# 183, Austin

83704

Novella Site# 247, Boise

Sponsors

Collaborators (1)

Novella Clinical

All Listed Sponsors

collaborator

Novella Clinical

OTHER

lead

Novan, Inc.

INDUSTRY

NCT03445013 - A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis | Biotech Hunter | Biotech Hunter